160 related articles for article (PubMed ID: 35046364)
1. [Long-Term Survival by Low-Dose Imatinib after Recurrence of GIST].
Mihara Y; Ando T; Hayashi M; Atsuta K; Nakayama T; Isobe K
Gan To Kagaku Ryoho; 2022 Jan; 49(1):63-65. PubMed ID: 35046364
[TBL] [Abstract][Full Text] [Related]
2. A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome.
Zhu J; Yang Y; Zhou L; Jiang M; Hou M
BMC Cancer; 2010 May; 10():199. PubMed ID: 20465813
[TBL] [Abstract][Full Text] [Related]
3. [A case of an elderly patient with recurrent GIST, which was effectively treated with low-dose imatinib mesylate].
Matsumoto S; Takahashi M; Ishizu H; Takahashi H; Masuko H; Tanaka K; Hata T; Yamagami H; Takahashi S; Tahara M; Ueki S; Kuji M; Tanioka T
Gan To Kagaku Ryoho; 2014 Nov; 41(12):2405-7. PubMed ID: 25731538
[TBL] [Abstract][Full Text] [Related]
4. Is imatinib justified as an adjuvant chemotherapy for patients with recurrent gastrointestinal stromal tumors.
Lai IR; Hu RH; Chang KJ
Hepatogastroenterology; 2005; 52(63):826-8. PubMed ID: 15966213
[TBL] [Abstract][Full Text] [Related]
5. Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial.
DeMatteo RP; Ballman KV; Antonescu CR; Corless C; Kolesnikova V; von Mehren M; McCarter MD; Norton J; Maki RG; Pisters PW; Demetri GD; Brennan MF; Owzar K;
Ann Surg; 2013 Sep; 258(3):422-9. PubMed ID: 23860199
[TBL] [Abstract][Full Text] [Related]
6. Emergence of secondary resistance to imatinib in recurrent gastric GIST.
Jayanthi NV
J Gastrointest Surg; 2010 Dec; 14(12):2018-9; author reply 2020. PubMed ID: 20714935
[No Abstract] [Full Text] [Related]
7. Long-term follow-up outcome of imatinib mesylate treatment for recurrent and unresectable gastrointestinal stromal tumors.
Saito S; Nakata K; Kajiura S; Ando T; Hosokawa A; Sugiyama T
Digestion; 2013; 87(1):47-52. PubMed ID: 23343969
[TBL] [Abstract][Full Text] [Related]
8. Improved outcome with multimodal treatment and imatinib rechallenge in advanced GIST.
Gasparotto D; Miolo G; Torrisi E; Canzonieri V; Bertola G; Libra M; Marzotto A; Maestro R; Buonadonna A
Int J Colorectal Dis; 2014 May; 29(5):639-40. PubMed ID: 24525699
[No Abstract] [Full Text] [Related]
9. Recurrent rectal GIST resected successfully after preoperative chemotherapy with imatinib mesylate.
Hamada M; Ozaki K; Horimi T; Tsuji A; Nasu Y; Iwata J; Nagata Y
Int J Clin Oncol; 2008 Aug; 13(4):355-60. PubMed ID: 18704638
[TBL] [Abstract][Full Text] [Related]
10. Reintroduction of imatinib in GIST.
Reid T
J Gastrointest Cancer; 2013 Dec; 44(4):385-92. PubMed ID: 23921604
[TBL] [Abstract][Full Text] [Related]
11. [Long-term survival in a case of recurrent gastrointestinal stromal tumor treated with intermittent or low-dose imatinib].
Kurata Y; Takaishi S; Sakuma Y; Iwasaki K; Nimura Y; Tohma T; Kagaya A; Yamamoto Y; Matsubara H
Gan To Kagaku Ryoho; 2014 Mar; 41(3):379-82. PubMed ID: 24743288
[TBL] [Abstract][Full Text] [Related]
12. Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China.
Du CY; Zhou Y; Song C; Wang YP; Jie ZG; He YL; Liang XB; Cao H; Yan ZS; Shi YQ
Eur J Cancer; 2014 Jul; 50(10):1772-1778. PubMed ID: 24768330
[TBL] [Abstract][Full Text] [Related]
13. Gastrointestinal stromal tumors: imatinib and beyond.
Schnadig ID; Blanke CD
Curr Treat Options Oncol; 2006 Nov; 7(6):427-37. PubMed ID: 17032555
[TBL] [Abstract][Full Text] [Related]
14. [Two cases of primary unresectable and/or recurrent gastrointestinal stromal tumors of small intestine presenting hemoperitoneum caused by administration of imatinib mesylate].
Yokoyama A; Dairaku N; Kusano M; Koshita S; Shimada N; Yamagiwa T; Kojima Y; Ojima T; Ikeya S; Nakayama H; Sugai Y; Hiwatashi N; Asano S
Nihon Shokakibyo Gakkai Zasshi; 2008 Nov; 105(11):1619-26. PubMed ID: 18987447
[TBL] [Abstract][Full Text] [Related]
15. Gastrointestinal stromal tumors: current management.
Pisters PW; Patel SR
J Surg Oncol; 2010 Oct; 102(5):530-8. PubMed ID: 20063363
[TBL] [Abstract][Full Text] [Related]
16. [A Case of Rectal GIST under Long-Term Follow-Up with Oral Imatinib].
Hasegawa K; Okamoto S; Hayakawa T; Takatsuno Y; Maejima K; Kaneko J; Isogai J
Gan To Kagaku Ryoho; 2022 Dec; 49(13):1470-1472. PubMed ID: 36733105
[TBL] [Abstract][Full Text] [Related]
17. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
Joensuu H; Eriksson M; Sundby Hall K; Hartmann JT; Pink D; Schütte J; Ramadori G; Hohenberger P; Duyster J; Al-Batran SE; Schlemmer M; Bauer S; Wardelmann E; Sarlomo-Rikala M; Nilsson B; Sihto H; Monge OR; Bono P; Kallio R; Vehtari A; Leinonen M; Alvegård T; Reichardt P
JAMA; 2012 Mar; 307(12):1265-72. PubMed ID: 22453568
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132.
Wang D; Zhang Q; Blanke CD; Demetri GD; Heinrich MC; Watson JC; Hoffman JP; Okuno S; Kane JM; von Mehren M; Eisenberg BL
Ann Surg Oncol; 2012 Apr; 19(4):1074-80. PubMed ID: 22203182
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant imatinib for GIST: the pie is shrinking.
Balachandran VP; DeMatteo RP
Ann Surg Oncol; 2014 Oct; 21(11):3365-6. PubMed ID: 25120253
[No Abstract] [Full Text] [Related]
20. Giant GIST of the small intestine in a young man.
Atmatzidis S; Chatzimavroudis G; Ananiadis A; Kapoulas S; Atmatzidis K
J Gastrointest Surg; 2013 Aug; 17(8):1536-7. PubMed ID: 23797887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
